• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Multidisciplinary Model Enhances Pediatric Immune Disorder Genomic Testing Yield and Care

by
November 19, 2026
in Health
Reading Time: 6 mins read
0
Multidisciplinary Model Enhances Pediatric Immune Disorder Genomic Testing Yield and Care

Multidisciplinary Model Enhances Pediatric Immune Disorder Genomic Testing Yield and Care

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comprehensive retrospective chart audit of 322 pediatric patients evaluated across eight years in Queensland, Australia, demonstrates that integrating a dedicated multidisciplinary model of care substantially improves clinical and health service outcomes for inborn errors of immunity. Published in the Journal of Clinical Immunology, the clinical investigation evaluated 481 genomic tests performed between 2017 and 2025 to determine diagnostic yield and service patterns before and after the introduction of a specialized framework. Inborn errors of immunity represent an extensive and heterogeneous group of rare genetic conditions affecting the immune system, causing heightened vulnerability to severe infections, autoimmunity, autoinflammation, allergies, and malignancies. While individually rare, their collective prevalence is estimated to fall between 1 in 1,000 and 1 in 5,000 individuals, frequently manifesting in childhood with life-limiting complications. Establishing a precise molecular diagnosis is crucial because targeted therapies, including hematopoietic stem cell transplantation, immunoglobulin replacement therapy, gene therapy, and specific antimicrobial or immunomodulatory prophylaxis, demonstrate maximal efficacy when initiated early in the disease trajectory before irreversible infectious complications or organ damage manifest.

Despite the recognized personal and clinical utility of genomic sequencing, practical integration into standard immunology care has historically been hindered by an absence of standardized guidelines addressing patient selection, informed consent, test modality choices, familial implications, and result communication. To overcome diagnostic inefficiencies and mitigate missed opportunities for targeted intervention, clinicians established a specialized multidisciplinary model of care at the Queensland Pediatric Immunology and Allergy Service, based at the Queensland Children’s Hospital. Serving a population of approximately 5.1 million spread across more than 1.7 million square kilometers, the tertiary service embedded multiple strategic structural components. These features encompassed monthly statewide multidisciplinary team meetings uniting pediatric and adult immunologists, clinical geneticists, genetic counselors, immunology and genetic pathologists, specialized nurses, and allied medical specialists. The model also incorporated an embedded genetic counselor directly within the immunology clinic, protected funding for a clinical immunologist specializing in immunogenomics, front-line trio whole-exome sequencing utilizing virtual panels, streamlined collaborative pathways with Pathology Queensland, and strong linkages with research networks through the Clinical Immunogenomics Research Consortium Australasia.

To evaluate the real-world operational and clinical performance of this clinical care structure, investigators audited consecutive pediatric patients aged 18 years or younger who underwent genomic testing for suspected inborn errors of immunity between 2017 and 2025. Following the exclusion of 40 individuals due to unverifiable reports, testing initiated past age 18, or non-immune indications, the final analyzed cohort comprised 322 children, with 10 deceased at the time of data extraction. The mean age at initial genomic evaluation was 5.9 years, ranging from birth to 17 years, and males represented 53.7 percent of the cohort based on biological sex. In terms of geographic distribution assessed via the Australian Statistical Geography Standard, 72.4 percent resided in major urban centers and 11.8 percent lived in inner regional localities, alongside 17 patients situated in Northern New South Wales. Nearly half of the participants lived in socioeconomically advantaged regions according to standard census index measures. Clinical presentations motivating evaluation were diverse, led by very early-onset inflammatory bowel disease in 21.1 percent of patients, immune dysregulation in 11.2 percent, atypical infections in 9.9 percent, antibody deficiencies in 9.9 percent, and autoinflammatory conditions in 8.7 percent, alongside two infants identified via severe combined immunodeficiency newborn screening introduced in May 2023.

Across the cohort, clinicians ordered a cumulative total of 481 genomic investigations, yielding an average of 1.5 tests per child with a range spanning from one to five tests. More than one-third of the children received two or more genomic tests over the study window. Ordering patterns highlighted widespread cross-specialty involvement beyond immunology alone: while pediatric immunologists initiated 51.8 percent of all test requests, gastroenterologists ordered 11.4 percent, clinical geneticists accounted for 7.7 percent, and rheumatologists initiated 4.4 percent. The audit identified 35 instances of redundant, duplicate testing among 115 multi-tested patients, split evenly between requests originated by different departments and repeat tests within the same specialty. These redundant orders encompassed 28 duplicate gene panels, six single-gene tests, and one repeat familial variant test conducted within intervals ranging from one month to two years without documented clinical justification. Excluding these duplicate requests left 446 unique genomic tests, of which 95.3 percent were arranged for proband diagnosis, 3.3 percent for pediatric cascade testing, 0.9 percent for variant segregation analysis, and 0.7 percent to assess donor suitability for hematopoietic stem cell transplantation.

Panel and virtual panel analyses represented the predominant unique testing modalities, comprising 65.9 percent of all investigations. Virtual panel testing, which filters comprehensive exome or genome sequencing data against curated disease-specific gene lists hosted on PanelApp Australia, was deployed as singleton analysis in 58.4 percent, trio testing in 40.0 percent, and duo testing in 1.6 percent of virtual panel requests. The integration of family-based trio analysis rose substantially over the study timeline, climbing from 18.1 percent before formal establishment to 66.7 percent of broad genomic assays from 2023 onward. Across 294 panel assays, clinicians applied 352 individual gene lists, of which 81.8 percent targeted immunological presentations, led by the immunological disorders super panel in 40.3 percent of applications, inflammatory bowel disease panels in 20.1 percent, and autoinflammatory disease lists in 11.8 percent. Non-immunological panels were also utilized across 64 instances to evaluate intersecting organ system involvement, covering respiratory, hematological, metabolic, neurological, dermatological, nephrological, and orthopedic phenotypes. Among 84 children undergoing longitudinal unique testing trajectories, 16 received expanded gene panels, five underwent bioinformatic panel re-analysis of previous sequencing data, and 10 progressed from targeted panels, chromosomal microarrays, or exomes to clinical whole-genome sequencing.

Overall diagnostic yield reached 26.7 percent across the cohort, identifying definitive pathogenic or likely pathogenic variants in accredited laboratories for 86 patients, including 10 syndromic presentations. When excluding familial cascade testing, the proband diagnostic rate was 20.2 percent. Diagnostic success varied markedly across clinical indications: patients presenting with phagocytic defects achieved a 100 percent diagnostic yield, while those evaluated for severe combined immunodeficiency reached an 80.0 percent yield, and syndromic presentations achieved 63.2 percent. In sharp contrast, children tested for autoinflammation showed a 7.1 percent yield, and those tested for very early-onset inflammatory bowel disease yielded a molecular diagnosis in only 4.4 percent of cases. Omitting the low-yield very early-onset inflammatory bowel disease group shifted the cohort diagnostic rate upward to 32.7 percent. Initial testing secured diagnoses for 81.4 percent of positive cases, whereas 18.6 percent required subsequent investigations, including modality shifts, expanded panels, or new single-gene analyses. Variants of uncertain significance were documented in 22.6 percent of unique tests, and non-diagnostic risk alleles, such as NOD2 and TACI variants associated with common variable immunodeficiency or Crohn’s disease, appeared in 3.4 percent.

Pathogenic variants mapped across 45 genes categorized under the International Union of Immunological Societies classification among 79 patients, alongside seven children whose confirmed molecular diagnoses involved non-immunological entities. The most frequently implicated immune genes were CD40LG in five patients, alongside BTK, STAT3, NCF1, and CTLA4 in four patients each. Primary immunodeficiencies affecting cellular and humoral immunity, alongside combined immunodeficiencies with associated or syndromic features, constituted the most common functional categories, each accounting for 14 patients. Inheritance modes spanned autosomal recessive mechanisms in 46.8 percent, autosomal dominant in 19.0 percent, X-linked in 17.7 percent, autosomal dominant gain-of-function in 8.9 percent, autosomal dominant loss-of-function with dominant-negative effects in 3.8 percent, simple loss-of-function in 2.5 percent, and dominant-negative mechanisms in 1.3 percent, with STAT3 variants uniquely illustrating both gain-of-function and loss-of-function presentations across different phenotypic classifications. Among 10 deceased children, six possessed molecular diagnoses spanning RAG1, CYBB, ADA2, G6PC3, NCF2, CHD7, or SAMD9, with mortality attributable equally to disease sequelae or post-transplant complications.

Establishing a definitive genetic diagnosis directly influenced patient management, with 89.9 percent of children possessing an immunological molecular diagnosis receiving formal management change recommendations. Major clinical adjustments occurred in 69.6 percent of cases, encompassing 29 recommendations for hematopoietic stem cell transplantation, 25 initiations of targeted molecular therapies or specialized management regimens, seven prophylaxis adjustments, three immunoglobulin replacement commencements, and one alteration of transplant conditioning chemotherapy to prevent cellular toxicity. Minor management modifications, centered primarily on customized surveillance, were instituted in 22.8 percent of patients. Observed clinical recommendations varied even among patients harboring identical genetic mutations or within families, reflecting phenotypic heterogeneity and testing timelines, such as earlier transplant coordination in presymptomatic relatives or diagnostic confirmation following empirical treatment. Only 8.7 percent experienced no recorded management change, either due to stable continuing regimens or unavailable records. Research integration further aided unresolved cases, with research pipelines securing diagnostic variants in CTLA4 and CXCR4 or executing functional assays to reclassify variants in CTLA4 and DOCK8.

Comparative evaluation between the pre-implementation period before 2021 and the post-implementation period from 2021 onward demonstrated significant systemic improvements across all measured health service metrics. Within service-initiated testing, diagnostic yield rose significantly from 14.5 percent pre-implementation to 27.4 percent post-implementation. Unwarranted duplicate testing was entirely eliminated, falling from 13.5 percent of requests prior to 2021 to zero percent thereafter. Concurrently, documented informed consent compliance increased from 70.5 percent to 88.4 percent, supported by structured pre-test genetic counseling and formal electronic filing workflows. The proportion of tests returning ambiguous variants of uncertain significance dropped from 37.7 percent to 7.1 percent, reflecting close collaboration with local public pathology teams participating in multidisciplinary variant review panels. Public laboratory engagement also shifted decisively, with Pathology Queensland handling 87.0 percent of service-initiated testing after 2021 compared to 16.6 percent previously. These empirical findings underscore how structured multidisciplinary governance successfully optimizes genomic healthcare delivery, rationalizes testing expenditures, and delivers timely, life-altering precision interventions for pediatric immune disorders.

Subject of Research: Clinical and health service outcomes of implementing a multidisciplinary genomic model of care for pediatric inborn errors of immunity

Article Title: Evaluating Genomic Testing in Pediatric Inborn Errors of Immunity: An Optimal Model of Care

Article References: DeBortoli, E., Clinch, T., Vaz-Gonçalves, L., Burbury, L., Thomas, C., Jeppesen, M., Pinzon-Charry, A., Melo, M., Sullivan, A., Hunter, M. F., Peake, J., McInerney-Leo, A., McNaughton, P., & Yanes, T. (2026). Evaluating Genomic Testing in Pediatric Inborn Errors of Immunity: An Optimal Model of Care. Journal of Clinical Immunology, 46(1), Article 102. https://doi.org/10.1007/s10875-026-02057-3

Image Credits: AI Generated

DOI: 10.1007/s10875-026-02057-3

Keywords: inborn errors of immunity, pediatric genomics, diagnostic yield, models of care, whole exome sequencing, multidisciplinary care, genetic counseling, clinical immunology, hematopoietic stem cell transplantation, variants of uncertain significance, very early onset inflammatory bowel disease, severe combined immunodeficiency, trio sequencing, PanelApp Australia, health service outcomes, Pathology Queensland

News Source: Harold Sullivan. (November 19, 2026). Multidisciplinary Model Enhances Pediatric Immune Disorder Genomic Testing Yield and Care. Scienmag.

Tags: clinical immunologydiagnostic yieldgenetic counselinghealth service outcomeshematopoietic stem cell transplantationinborn errors of immunitymodels of caremultidisciplinary carePanelApp AustraliaPathology Queenslandpediatric genomicssevere combined immunodeficiencytrio sequencingVariants of uncertain significancevery early onset inflammatory bowel diseasewhole-exome sequencing
Share12Tweet7Share2ShareShareShare1

Related Posts

Sphingomyelins Inversely Associate with Atherogenic sdLDL Particle Ratio in Cross-Sectional Study

Sphingomyelins Inversely Associate with Atherogenic sdLDL Particle Ratio in Cross-Sectional Study

November 19, 2026
Dual Normal CA19-9 and DUPAN-2 Predicts Improved Survival in Pancreatic Cancer

Dual Normal CA19-9 and DUPAN-2 Predicts Improved Survival in Pancreatic Cancer

November 19, 2026

Heat and Humidity Challenge Endurance Athletes as Researchers Propose Standardised Testing

November 19, 2026

Psoriasis Mimic Diagnosed as Pemphigus Foliaceus via Detailed Tissue Pathology

November 19, 2026

POPULAR NEWS

  • Lifelong Social Isolation Tied to Muscle Weakness but Lower Obesity Odds

    Lifelong Social Isolation Tied to Muscle Weakness but Lower Obesity Odds

    29 shares
    Share 12 Tweet 7
  • Narrative Review Identifies Systematic Bias and Privacy Risks Across AI Electrocardiography Protocols

    29 shares
    Share 12 Tweet 7
  • Landscape Integrated Farming Framework Links Cross-Farm Resources to Enhance Climate Resilience

    29 shares
    Share 12 Tweet 7
  • Machine Learning Matches Traditional Time Series in Forecasting Tanzanian Sisal Exports

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Sphingomyelins Inversely Associate with Atherogenic sdLDL Particle Ratio in Cross-Sectional Study

Review Assesses Zanubrutinib Across Clinical Trials in Chronic Lymphocytic Leukemia

Dual Normal CA19-9 and DUPAN-2 Predicts Improved Survival in Pancreatic Cancer

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.